

# E Guttman-Yassky

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6875618/publications.pdf>

Version: 2024-02-01

55  
papers

2,589  
citations

257101

24  
h-index

205818

48  
g-index

56  
all docs

56  
docs citations

56  
times ranked

2430  
citing authors

#	ARTICLE	IF	CITATIONS
1	EAACI Biologicals Guidelines "Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 17-38.	2.7	19
2	Response to "Lack of efficacy of dupilumab in the treatment of keloid disorder"™ by MH Tirgan and J Uitto. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	1.3	0
3	Early intervention and prevention of allergic diseases. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 416-441.	2.7	44
4	Phase 2a randomized clinical trial of dupilumab (anti-IL-4R $\alpha$ ) for alopecia areata patients. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 897-906.	2.7	51
5	P573 The safety profile of upadacitinib maintenance therapy in ulcerative colitis in the Phase 3 U-ACHIEVE study is consistent with that in approved indications. Journal of Crohn's and Colitis, 2022, 16, i514-i514.	0.6	6
6	Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery. Nature Medicine, 2022, 28, 626-629.	15.2	12
7	Obesity alters pathology and treatment response in inflammatory disease. Nature, 2022, 604, 337-342.	13.7	93
8	Distinct skin microbiome community structures in congenital ichthyosis. British Journal of Dermatology, 2022, 187, 557-570.	1.4	11
9	Analysis of alopecia areata surveys suggests a threshold for improved patient-reported outcomes. British Journal of Dermatology, 2022, 187, 539-547.	1.4	7
10	Tape strips from early-onset pediatric atopic dermatitis highlight disease abnormalities in nonlesional skin. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 314-325.	2.7	61
11	Evidence for different immune signatures and sensitization patterns in sub-Saharan African vs. Central European atopic dermatitis patients. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e140-e142.	1.3	14
12	Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 45-58.	2.7	41
13	Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 59-70.	2.7	58
14	SARS-CoV-2 receptor ACE2 protein expression in serum is significantly associated with age. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 875-878.	2.7	29
15	Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)*. British Journal of Dermatology, 2021, 184, 437-449.	1.4	289
16	The erythema Q-score, an imaging biomarker for redness in skin inflammation. Experimental Dermatology, 2021, 30, 377-383.	1.4	8
17	Whole genome sequencing identifies novel genetic mutations in patients with eczema herpeticum. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2510-2523.	2.7	20
18	Priority research questions in atopic dermatitis: an International Eczema Council eDelphi consensus. British Journal of Dermatology, 2021, 185, 203-205.	1.4	3

#	ARTICLE	IF	CITATIONS
19	High-dimensional analysis defines multicytokine T cell subsets and supports a role for IL-21 in atopic dermatitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3080-3093.	2.7	6
20	Selective sweep for an enhancer involucrin allele identifies skin barrier adaptation out of Africa. <i>Nature Communications</i> , 2021, 12, 2557.	5.8	5
21	Atopic dermatitis among children and adolescents in the Arctic region – a systematic review and meta-analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1642-1654.	1.3	5
22	A plea for standardization of confocal microscopy and optical coherence tomography parameters to evaluate physiological and para-physiological skin conditions in cosmetic science. <i>Experimental Dermatology</i> , 2021, 30, 911-922.	1.4	14
23	Vascular inflammation in moderate-to-severe atopic dermatitis is associated with enhanced Th2 response. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3107-3121.	2.7	23
24	An integrated scalp and blood biomarker approach suggests the systemic nature of alopecia areata. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3053-3065.	2.7	15
25	Single-cell analysis of human skin identifies CD14+ type 3 dendritic cells co-producing IL1B and IL23A in psoriasis. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	68
26	T <sub>H</sub> 2 cytokines and <i>Staphylococcus aureus</i> cooperatively induce atopic dermatitis-like transcriptomes. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3534-3537.	2.7	7
27	Pioneering global best practices in atopic dermatitis: results from the atopic dermatitis quality of care initiative. <i>Clinical and Experimental Dermatology</i> , 2021, , .	0.6	1
28	EAACI Biologicals Guidelines – dupilumab for children and adults with moderate-to-severe atopic dermatitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 988-1009.	2.7	24
29	The role of circulating eosinophils on COVID-19 mortality varies by race/ethnicity. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 925-927.	2.7	14
30	Keloid lesions show increased IL-4/IL-13 signaling and respond to Th2-targeting dupilumab therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e161-e164.	1.3	50
31	International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale. <i>BMJ Open</i> , 2020, 10, e039928.	0.8	8
32	Chronic hand eczema understanding has ramifications on clinical management. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e429-e430.	1.3	11
33	Frontal fibrosing alopecia shows robust T helper 1 and Janus kinase 3 skewing. <i>British Journal of Dermatology</i> , 2020, 183, 1083-1093.	1.4	40
34	Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. <i>British Journal of Dermatology</i> , 2020, 183, 242-255.	1.4	277
35	Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges. <i>Therapeutics and Clinical Risk Management</i> , 2020, Volume 16, 1319-1332.	0.9	18
36	Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy – international eczema council survey and opinion. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1224-1231.	1.3	50

#	ARTICLE	IF	CITATIONS
37	544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1). <i>Journal of Investigative Dermatology</i> , 2019, 139, S94.	0.3	5
38	Conjunctivitis in dupilumab clinical trials. <i>British Journal of Dermatology</i> , 2019, 181, 459-473.	1.4	288
39	Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey-based position statement. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 807-815.	1.3	15
40	The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study. <i>British Journal of Dermatology</i> , 2019, 181, 733-742.	1.4	96
41	Atopic dermatitis in diverse racial and ethnic groups—Variations in epidemiology, genetics, clinical presentation and treatment. <i>Experimental Dermatology</i> , 2018, 27, 340-357.	1.4	209
42	Alopecia areata is characterized by expansion of circulating Th2/Tc2/Th22, within the skin-homing and systemic T cell populations. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 713-723.	2.7	45
43	Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. <i>British Journal of Dermatology</i> , 2018, 178, 768-775.	1.4	127
44	Incident alopecia areata and vitiligo in adult women with atopic dermatitis: Nurses' Health Study 2. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 831-834.	2.7	33
45	Nonlesional atopic dermatitis skin shares similar T cell clones with lesional tissues. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 2017-2025.	2.7	62
46	Dust mite induces multiple polar T cell axes in human skin. <i>Clinical and Experimental Allergy</i> , 2017, 47, 1648-1660.	1.4	22
47	Identification of unique proteomic signatures in allergic and non-allergic skin disease. <i>Clinical and Experimental Allergy</i> , 2017, 47, 1456-1467.	1.4	45
48	Circulating CLA <sup>+</sup> T cells in atopic dermatitis and their possible role as peripheral biomarkers. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 366-372.	2.7	40
49	Moderate-to-severe atopic dermatitis patients show increases in serum C-reactive protein levels, correlating with skin disease activity. <i>F1000Research</i> , 2017, 6, 1712.	0.8	23
50	Atopic dermatitis patients show increases in serum C-reactive protein levels, correlating with skin disease activity. <i>F1000Research</i> , 2017, 6, 1712.	0.8	18
51	Ustekinumab as therapy for psoriasis in a 2-year-old girl. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, e109-e110.	1.3	8
52	Global Allergy Forum and 3rd Davos Declaration 2015. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 588-592.	2.7	47
53	Î <sup>Î</sup> Np63 regulates IL-33 and IL-31 signaling in atopic dermatitis. <i>Cell Death and Differentiation</i> , 2016, 23, 1073-1085.	5.0	38
54	Chronic idiopathic urticaria: what is the meaning of skin reactivity to autologous serum? A response. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008, 22, 136-136.	1.3	1

#	ARTICLE	IF	CITATIONS
55	Psoriasis: evolution of pathogenic concepts and new therapies through phases of translational research. <i>British Journal of Dermatology</i> , 2007, 157, 1103-1115.	1.4	65